Bulletin
Investor Alert

New York Markets After Hours

July 28, 2021, 1:13 p.m. EDT

Companion Diagnostics Market Global Size, Share, Growth, Trends, Revenue Analysis, Competitive Landscape, Forecast 2028

The global Companion Diagnostics market report covers detailed study with the underlying influencing factors for the variations in the industry growth trends. The report scope includes market analysis on regional as well as country level.

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

Jul 28, 2021 (Heraldkeepers) -- The companion diagnostics market is expected to cross more than USD 6.8 billion by 2026 at a CAGR of 12.9%.

Browse Full Report: https://www.marketresearchengine.com/companion-diagnostics-market-size

Global Companion Diagnostics market is segmented based on the Indication as, Breast, Lung & Colorectal Cancer, Cardiovascular Disease. On the basis of Technology, the global Companion Diagnostics market is segregated as NGS, PCR, IHC ISH. On the basis of Product & Service Assay, Software & Service, Assay The report segments global Companion Diagnostics market based on End-User as CRO, Pharma Companies.

Market Research Engine has published a new report titled as " Companion Diagnostics Market Size, By Indication (Breast, Lung & Colorectal Cancer, Cardiovascular Disease), By Technology (PCR, NGS, ISH, IHC), By Product & Service (Assay, Kit, Software & Service) By End-User (Pharma Companies, CRO), By Region, Market Analysis Report, Forecast 2021-2026-Executive Data Report.''

Global Companion Diagnostics market report covers various regions including North America, Europe, Asia Pacific, and Rest of World. The regional Companion Diagnostics market is further bifurcated for major countries including U.S., Canada, Germany, UK, France, Italy, China, India, Japan, Brazil, South Africa and others.

This Companion Diagnostics market study offers a comprehensive analysis of the business models, key strategies, and respective market shares of a number of the foremost prominent players during this landscape. Alongside an in-depth commentary on the key influencing factors, market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data are offered within the full study. This study is one among the foremost comprehensive documentation that captures all the facets of the evolving Companion Diagnostics market. Such epidemic condition is being tailgated by the necessity of safe and effective and specific use of the drug. due to such demands, companion diagnostic drug market is poised for exponential growth. Companion diagnostics is an in-vitro diagnostic tool that assists physicians in optimizing treatment decisions for his or her patients and is crucial for myriad of cancer and other therapies. Riding on the rear of economic burden of worldwide healthcare and with abundant potential to limit the liability, these are medical instruments that support doctors to elect which treatment and dosage should tend to patients personalized to their necessity. Companion Diagnostics is employed to determine who would enjoy treatment and it comes in handy to spot if someone can’t be cured, but also conversely are often harmed by use of specific drug used for his or her ailment. Technological advancements have brought tons of changes within the method of disease treatment. Companion diagnostics is characterized by growing requirement for enhanced personalized patient treatment that provides healthcare providers and their patients an assurance about the treatment end in a positive way, contrary to traditional treatment procedure. Major impact of companion diagnostic is going to be been on oncology therapy area.

Research Methodology:

To calculate the market size, the report considers the revenue generated from the sales of Companion Diagnostics market manufacturers. The revenue generated from the sales of Companion Diagnostics manufacturer has been calculated through primary and secondary research.

The market size estimation also considered leading players revenues as part of triangulation The key players considered are F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies, Inc. (US), QIAGEN N.V. (Germany), Abbott Laboratories, Inc. (US), Almac Group (UK), Danaher Corporation (US), Illumina, Inc. (US), bioMerieux SA (France), Myriad Genetics, Inc., (US), Sysmex Corporation (Japan), Thermo Fisher Scientific Inc. (US), Abnova Corporation (Taiwan), and Guardant Health, Inc. (US). in the Companion Diagnostics market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes types of segmentation determined using secondary sources and verified through primary sources.

TheCompanion Diagnostics Market has been segmented as below:

Companion Diagnostics Market, By Indication

  • Infectious Diseases

  • Cardiovascular Diseases

  • Neurological Diseases

  • Cancer

  • Others

Companion Diagnostics Market, By Technology

  • Immunohistochemistry (IHC)

  • in Situ Hybridization (ISH)

  • Polymerase Chain Reaction (PCR)

  • Next-Generation Sequencing (NGS)

  • Other Technologies

Companion Diagnostics Market, By Product & Service

  • Software & Services

  • Assays, Kits, & Reagents

Companion Diagnostics Market, By End-User

  • Contract Research Organizations

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.